Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 17/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925849 | 1.00 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2USP2 | |
| SCHEMBL6925853 | 1.00 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2USP2 | |
| SCHEMBL8480309 | 0.90 | ADRB3 (0.61) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL8480311 | 0.90 | ADRB3 (0.61) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL8480316 | 0.90 | ADRB3 (0.61) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL667781 | 0.89 | ADRB3 (0.62) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL667783 | 0.89 | ADRB3 (0.62) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL667782 | 0.89 | ADRB3 (0.62) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL3704286 | 0.87 | ADRB3 (0.60) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL3704284 | 0.87 | ADRB3 (0.60) | ADRB3ADRB1ALOX15ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | claimed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | ADRB3 110/4885ADRB1 163/4885ALOX15 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.